| scholarly article | Q13442814 |
| P50 | author | Sadayoshi Itō | Q30932255 |
| P2093 | author name string | Hiroshi Sato | |
| Emiko Sato | |||
| Nobuyuki Takahashi | |||
| Junichi Sugawara | |||
| Kiyomi Kisu | |||
| Yuji Oe | |||
| Akiyo Sekimoto | |||
| Tomofumi Fushima | |||
| P2860 | cites work | VEGF inhibition and renal thrombotic microangiopathy | Q24632792 |
| Crosstalk in glomerular injury and repair | Q28085092 | ||
| Endothelial NO synthase genotype and risk of preeclampsia: a multicenter case-control study | Q28281936 | ||
| Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury | Q28286412 | ||
| Proangiogenic effects of protease-activated receptor 2 are tumor necrosis factor-alpha and consecutively Tie2 dependent | Q28567109 | ||
| Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia | Q29615916 | ||
| Chemokines as mediators of neovascularization | Q30438032 | ||
| CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis. | Q30596736 | ||
| Activation of protease-activated receptor 2 induces VEGF independently of HIF-1. | Q31103929 | ||
| Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. | Q33230191 | ||
| Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy | Q33410553 | ||
| Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature | Q33416857 | ||
| Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies | Q34080920 | ||
| The role of VEGF-A in glomerular development and function | Q34314360 | ||
| TLR2 and TLR4 mediate differential responses to limb ischemia through MyD88-dependent and independent pathways | Q34500561 | ||
| The Detection of Urinary Podocytes from Drug-Induced Glomerular Thrombotic Microangiopathy in Advanced Cancer Patients. | Q50909982 | ||
| PAR2-SMAD3 in microvascular endothelial cells is indispensable for vascular stability via tissue factor signaling. | Q53247182 | ||
| Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. | Q53579565 | ||
| Expression of vascular endothelial growth factor in human umbilical vein endothelial cells stimulated with interleukin-1alpha--an autocrine regulation of angiogenesis and inflammatory reactions | Q74006140 | ||
| Nitric oxide and angiogenesis | Q78057257 | ||
| Tandem mass spectrometry measurements of creatinine in mouse plasma and urine for determining glomerular filtration rate | Q79408625 | ||
| Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice | Q80305250 | ||
| Increased urinary excretion of nephrin, podocalyxin, and βig-h3 in women with preeclampsia | Q83388487 | ||
| High-mobility group box-1 mediates toll-like receptor 4-dependent angiogenesis | Q83524736 | ||
| Roles of coagulation pathway and factor Xa in the progression of diabetic nephropathy in db/db mice | Q84236710 | ||
| Subcellular localization of coagulation factor II receptor-like 1 in neurons governs angiogenesis | Q85302060 | ||
| Angiogenesis mediated by toll-like receptor 4 in ischemic neural tissue | Q85653931 | ||
| Urinary podocyte excretion and proteinuria in patients treated with antivascular endothelial growth factor therapy for solid tumor malignancies | Q88026834 | ||
| Glomerular endothelial cell injury and damage precedes that of podocytes in adriamycin-induced nephropathy | Q34566167 | ||
| Protease-activated receptor (PAR)2, but not PAR1, is involved in collateral formation and anti-inflammatory monocyte polarization in a mouse hind limb ischemia model. | Q34700750 | ||
| Vascular endothelial growth factor receptor 2 direct interaction with nephrin links VEGF-A signals to actin in kidney podocytes | Q35562791 | ||
| eNOS deficiency acts through endothelin to aggravate sFlt-1-induced pre-eclampsia-like phenotype | Q35853296 | ||
| Protease-activated receptor-2 augments experimental crescentic glomerulonephritis | Q35963188 | ||
| Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome | Q36890849 | ||
| Abnormal angiogenesis in diabetic nephropathy. | Q37236268 | ||
| Obesity promotes breast cancer by CCL2-mediated macrophage recruitment and angiogenesis | Q37298848 | ||
| Nicotinamide benefits both mothers and pups in two contrasting mouse models of preeclampsia | Q37451322 | ||
| Permanent cell line expressing human factor VIII-related antigen established by hybridization | Q37615209 | ||
| Pre-eclampsia: relationship between coagulation, fibrinolysis and inflammation | Q37796300 | ||
| Protease-activated receptor 2 signaling in inflammation | Q37942473 | ||
| High-mobility group box-1 and its role in angiogenesis | Q38181042 | ||
| Inhibition of the VEGF signalling pathway and glomerular disorders. | Q38284055 | ||
| Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis | Q38592152 | ||
| Exosomes from high glucose-treated glomerular endothelial cells trigger the epithelial-mesenchymal transition and dysfunction of podocytes | Q38609396 | ||
| Coagulation Factor Xa and Protease-Activated Receptor 2 as Novel Therapeutic Targets for Diabetic Nephropathy. | Q38765383 | ||
| Protease-activated receptor 2 exacerbates adenine-induced renal tubulointerstitial injury in mice. | Q39063513 | ||
| Protein kinase C alpha promotes angiogenic activity of human endothelial cells via induction of vascular endothelial growth factor. | Q40040832 | ||
| Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis | Q40158269 | ||
| Cathepsin S Cleavage of Protease-Activated Receptor-2 on Endothelial Cells Promotes Microvascular Diabetes Complications. | Q40322521 | ||
| Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression | Q40868885 | ||
| Production of vascular endothelial growth factor by murine macrophages: regulation by hypoxia, lactate, and the inducible nitric oxide synthase pathway | Q41015545 | ||
| Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. | Q41575948 | ||
| Elevated tissue factor expression contributes to exacerbated diabetic nephropathy in mice lacking eNOS fed a high fat diet | Q42971825 | ||
| Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer | Q46374116 | ||
| In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy | Q46549052 | ||
| Hepatic dysfunction and thrombocytopenia induced by excess sFlt1 in mice lacking endothelial nitric oxide synthase | Q49751930 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2986 | |
| P577 | publication date | 2019-02-27 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | Protease-activated receptor 2 protects against VEGF inhibitor-induced glomerular endothelial and podocyte injury | |
| P478 | volume | 9 |
| Q90571160 | Dual blockade of protease-activated receptor 1 and 2 additively ameliorates diabetic kidney disease | cites work | P2860 |
Search more.